Harith Rajagopalan, Fractyl Health CEO

Bet­ting on pub­lic mar­ket de­mand for more obe­si­ty ther­a­pies, Fractyl Health files for IPO to back gene ther­a­py

A week af­ter one obe­si­ty biotech, Car­mot Ther­a­peu­tics, backed out of its IPO plans in fa­vor of a $2.7 bil­lion sale to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.